JP2005509607A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509607A5 JP2005509607A5 JP2003532094A JP2003532094A JP2005509607A5 JP 2005509607 A5 JP2005509607 A5 JP 2005509607A5 JP 2003532094 A JP2003532094 A JP 2003532094A JP 2003532094 A JP2003532094 A JP 2003532094A JP 2005509607 A5 JP2005509607 A5 JP 2005509607A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- composition
- cancer
- seq
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 201000011510 cancer Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102000011727 Caspases Human genes 0.000 claims 2
- 108010076667 Caspases Proteins 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000025084 cell cycle arrest Effects 0.000 claims 2
- 230000008619 cell matrix interaction Effects 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000006882 induction of apoptosis Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000035407 negative regulation of cell proliferation Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 210000002437 synoviocyte Anatomy 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000003098 cholesteric effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32688401P | 2001-10-03 | 2001-10-03 | |
| PCT/IB2002/004065 WO2003028764A1 (en) | 2001-10-03 | 2002-10-03 | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005509607A JP2005509607A (ja) | 2005-04-14 |
| JP2005509607A5 true JP2005509607A5 (enExample) | 2006-01-05 |
| JP4405259B2 JP4405259B2 (ja) | 2010-01-27 |
Family
ID=23274136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003532094A Expired - Fee Related JP4405259B2 (ja) | 2001-10-03 | 2002-10-03 | 治療的に有用なトリエチレングリコールコレステリルオリゴヌクレオチド |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7635686B2 (enExample) |
| EP (1) | EP1432450B1 (enExample) |
| JP (1) | JP4405259B2 (enExample) |
| KR (1) | KR100971571B1 (enExample) |
| CN (1) | CN100352510C (enExample) |
| AT (1) | ATE314096T1 (enExample) |
| AU (1) | AU2002341264B2 (enExample) |
| CA (1) | CA2462425A1 (enExample) |
| DE (1) | DE60208400T2 (enExample) |
| DK (1) | DK1432450T3 (enExample) |
| ES (1) | ES2250713T3 (enExample) |
| IL (2) | IL161181A0 (enExample) |
| MX (1) | MXPA04002530A (enExample) |
| PT (1) | PT1432450E (enExample) |
| WO (1) | WO2003028764A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60036019T2 (de) * | 1999-12-13 | 2008-05-29 | Bioniche Life Sciences Inc., Belleville | Synthetische oligonukleotide die therapeutisch nützlich sind |
| US7491805B2 (en) * | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| CN101160399A (zh) * | 2002-04-22 | 2008-04-09 | 拜奥尼茨生命科学公司 | 寡核苷酸组合物及其在调节免疫应答中的应用 |
| GB2443591B (en) * | 2005-09-07 | 2010-04-28 | Secr Defence | Adjuvanted vaccine |
| US20090054366A1 (en) * | 2007-06-15 | 2009-02-26 | Reliance Life Sciences Pvt. Ltd. | RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY |
| GB0906234D0 (en) | 2009-04-14 | 2009-05-20 | Secr Defence | Vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4958013A (en) * | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| DE69434614T2 (de) * | 1993-11-30 | 2006-10-05 | Tanox, Inc., Houston | Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung |
| US5756668A (en) * | 1994-11-15 | 1998-05-26 | The Johns Hopkins University School Of Medicine | Hypermethylated in cancer polypeptide, HIC-1 |
| US5643890A (en) | 1995-01-31 | 1997-07-01 | The Board Of Regents Of The University Of Nebraska | Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases |
| WO1997014440A1 (en) | 1995-10-19 | 1997-04-24 | Johnson & Johnson Interventional Systems | Conjugation of c-myc antisense oligonucleotides with cholesterol to significantly enhance their inhibitory effect on neointimal hyperplasia |
| US5958780A (en) * | 1997-06-30 | 1999-09-28 | Boston Advanced Technologies, Inc. | Method for marking and identifying liquids |
| AU9220498A (en) | 1997-09-04 | 1999-03-22 | Bayer Corporation | Oligonucleotide probes bearing quenchable fluorescent labels, and methods of usethereof |
| EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| DE60036019T2 (de) * | 1999-12-13 | 2008-05-29 | Bioniche Life Sciences Inc., Belleville | Synthetische oligonukleotide die therapeutisch nützlich sind |
| US7087586B2 (en) * | 2001-04-24 | 2006-08-08 | Bioniche Life Sciences, Inc. | Oligonucleotide compositions and their use to induce differentiation of cells |
| WO2002092006A2 (en) * | 2001-05-16 | 2002-11-21 | Micrologix Biotech, Inc. | Nucleic acid-based compounds and methods of use thereof |
-
2002
- 2002-10-03 IL IL16118102A patent/IL161181A0/xx unknown
- 2002-10-03 CN CNB028241916A patent/CN100352510C/zh not_active Expired - Fee Related
- 2002-10-03 PT PT02775055T patent/PT1432450E/pt unknown
- 2002-10-03 DE DE60208400T patent/DE60208400T2/de not_active Expired - Lifetime
- 2002-10-03 ES ES02775055T patent/ES2250713T3/es not_active Expired - Lifetime
- 2002-10-03 JP JP2003532094A patent/JP4405259B2/ja not_active Expired - Fee Related
- 2002-10-03 US US10/264,280 patent/US7635686B2/en not_active Expired - Fee Related
- 2002-10-03 DK DK02775055T patent/DK1432450T3/da active
- 2002-10-03 AT AT02775055T patent/ATE314096T1/de active
- 2002-10-03 WO PCT/IB2002/004065 patent/WO2003028764A1/en not_active Ceased
- 2002-10-03 EP EP02775055A patent/EP1432450B1/en not_active Expired - Lifetime
- 2002-10-03 MX MXPA04002530A patent/MXPA04002530A/es active IP Right Grant
- 2002-10-03 AU AU2002341264A patent/AU2002341264B2/en not_active Ceased
- 2002-10-03 CA CA002462425A patent/CA2462425A1/en not_active Abandoned
- 2002-10-03 KR KR1020047004837A patent/KR100971571B1/ko not_active Expired - Fee Related
-
2004
- 2004-03-30 IL IL161181A patent/IL161181A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505588A5 (enExample) | ||
| JP2003509343A5 (enExample) | ||
| JP2005500357A5 (enExample) | ||
| JP2006504723A5 (enExample) | ||
| IL164373A (en) | Benzamide derivatives, pharmaceutical compositions containing them, process for their preparation and use thereof in the manufacture of medicaments and as medicaments in the treatment of diseases associated with cancer | |
| CY1107850T1 (el) | Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους | |
| GB0022438D0 (en) | Organic Compounds | |
| MY148108A (en) | Medicaments for the treatment or prevention of fibrotic diseases | |
| MY144616A (en) | Substituted dihydroquinazolines | |
| MY124853A (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives. | |
| IL163817A (en) | Derivatives of –4,2 Diaminopyrimidine, Process for Preparation, Pharmaceutical Preparations Containing Them, and Use in Preparation of Breast Cancer Drugs | |
| ATE237330T1 (de) | Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung | |
| TW200640499A (en) | Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments | |
| NZ601544A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| TW200500067A (en) | Salts of codrugs and uses related thereto | |
| CA2431565A1 (en) | Pharmaceutical compositions based on anticholinergics and ciclesonide | |
| MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
| CY1112184T1 (el) | Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii | |
| WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| JP2005507892A5 (enExample) | ||
| JP2006514116A5 (enExample) | ||
| JP2006503904A5 (enExample) | ||
| DE602004016376D1 (de) | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs | |
| JP2021520804A5 (enExample) | ||
| JP2010500284A5 (enExample) |